Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat

6-Hydroxydopamine-induced nerve terminal lesion of the nigrostriatal system may provide a partial lesion model of Parkinson's disease useful for the assessment of neuroprotective treatments and behavioral recovery after therapeutic intervention. The aim of the present study was to assess the retrograde degenerative changes in the dopaminergic neurons of the substantia nigra and the associated behavioral and neurochemical consequences of intrastriatal injections of 6-hydroxydopamine in young adult rats. Four groups of rats were stereotaxically injected in the right striatum with graded doses of 6-hydroxydopamine ranging from 0 to 20 mu g. Structural and functional deficits were quantified by tyrosine hydroxylase-immunoreactive nigral cell numbers, striatal dopamine content, skilled paw use, and drug-induced rotation. The results show that striatal 6-hydroxydopamine lesions produce dose-dependent decreases in striatal dopamine levels and tyrosine hydroxylase-immunoreactive cell numbers in the ipsilateral substantia nigra, accompanied by a significant long-lasting atrophy of the remaining dopaminergic neurons. Paw reaching test scores on the side contralateral to the lesion were non-linearly correlated with dopaminergic neuronal cell loss and exhibited a clear symptomatic threshold such that impaired paw use appeared only after >50% loss of nigral dopamine neurons or a reduction of 60-80% of striatal dopamine levels. The behavioral, cellular, and neurochemical effects of the nerve terminal lesion thus bear some resemblance to the early stages of Parkinson's disease, where the severity of motor impairment is correlated with the loss of dopamine in the striatum and dopaminergic neuronal loss in the substantia nigra. Rats with intrastriatal 6-hydroxydopamine lesions thus provide a model of progressive dopamine neuron degeneration useful not only for the exploration of neuroprotective therapeutic intervention but also for the study of mechanisms of functional and structural recovery after subtotal damage of the nigrostriatal dopamine system.

[1]  D. Togasaki,et al.  Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine , 1995, Neuroscience.

[2]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[3]  C. D. Stern,et al.  Handbook of Chemical Neuroanatomy Methods in Chemical Neuroanatomy. Edited by A. Bjorklund and T. Hokfelt. Elsevier, Amsterdam, 1983. Cloth bound, 548 pp. UK £140. (Volume 1 in the series). , 1986, Neurochemistry International.

[4]  K. Fuxe,et al.  EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS. , 1964, Acta physiologica Scandinavica. Supplementum.

[5]  S. Dunnett,et al.  The “staircase test”: a measure of independent forelimb reaching and grasping abilities in rats , 1991, Journal of Neuroscience Methods.

[6]  C. Olanow.  A radical hypothesis for neurodegeneration , 1993, Trends in Neurosciences.

[7]  H. Okamura,et al.  Degeneration of the nigral dopamine neurons after 6-hydroxydopamine injection into the rat striatum , 1991, Brain Research.

[8]  Ian Q. Whishaw,et al.  Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats , 1988, Brain Research.

[9]  A. Grace,et al.  Compensations after lesions of central dopaminergic neurons: some clinical and basic implications , 1990, Trends in Neurosciences.

[10]  A. Björklund,et al.  Functional Activity of Substantia Nigra Grafts Reinnervating the Striatum: Neurotransmitter Metabolism and [14C]2‐Deoxy‐d‐glucose Autoradiography , 1982, Journal of neurochemistry.

[11]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[12]  G. Lahoste,et al.  Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists , 1990, Behavioural Brain Research.

[13]  P. Kelly,et al.  Nigral dopaminergic mechanisms in drug-induced circling , 1983, Brain Research Bulletin.

[14]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[15]  W. H. Oertel,et al.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.

[16]  P. Bédard,et al.  Decrease of behavioral and biochemical denervation supersensitivity of rat striatum by nigral transplants , 1991, Neuroscience.

[17]  M Schulzer,et al.  Clinical observations on the rate of progression of idiopathic parkinsonism. , 1994, Brain : a journal of neurology.

[18]  Y. Agid,et al.  Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. , 1973, Nature: New biology.

[19]  N. Osborne.  Handbook of chemical neuroanatomy, Vol. 2: Classical Transmitters in the CNS Part 1. Edited by A. Björklund and T. Hökfelt. ISBN 0444 90330 5. Price: $104. Elsevier, 1984 , 1986, Neurochemistry International.

[20]  S. Kish,et al.  Aging Produces a Specific Pattern of Striatal Dopamine Loss: Implications for the Etiology of Idiopathic Parkinson's Disease , 1992, Journal of neurochemistry.

[21]  U. Ungerstedt,et al.  Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. , 1970, Brain research.

[22]  G. Nikkhah,et al.  Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[23]  P. Riederer,et al.  Oxygen Free Radicals and Neurodegeneration in Parkinson's Disease: A Role for Nitric Oxide a , 1994, Annals of the New York Academy of Sciences.

[24]  U. Ungerstedt,et al.  In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. , 1988, European journal of pharmacology.

[25]  J. Cadet,et al.  Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen , 1991, Brain Research Bulletin.

[26]  David M. A. Mann,et al.  Possible role of neuromelanin in the pathogenesis of Parkinson's disease , 1983, Mechanisms of Ageing and Development.

[27]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Archer,et al.  Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease , 1990, Brain Research.

[29]  J. Cadet,et al.  Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats , 1991, Brain Research Bulletin.

[30]  S. Snyder,et al.  Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. , 1977, Science.

[31]  R. Wurtman,et al.  Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization , 1980, Brain Research.

[32]  A. Björklund,et al.  Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[34]  H. Robertson,et al.  Dopamine receptor interactions: some implications for the treatment of Parkinson's disease , 1992, Trends in Neurosciences.

[35]  R. H. Stellwagen,et al.  Slow changes of tyrosine hydroxylase gene expression in dopaminergic brain neurons after neurotoxin lesioning: a model for neuron aging. , 1992, Brain research. Molecular brain research.

[36]  H. Okamura,et al.  Biochemical and Immunocytochemical Changes Induced by Intrastriatal 6-Hydroxydopamine Injection in the Rat Nigrostriatal Dopamine Neuron System: Evidence for Cell Death in the Substantia Nigra , 1994, Experimental Neurology.

[37]  C. Altar,et al.  Time Course of Adaptations in Dopamine Biosynthesis, Metabolism, and Release Following Nigrostriatal Lesions: Implications for Behavioral Recovery from Brain Injury , 1987, Journal of neurochemistry.